These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 10987049)

  • 41. Combined chemotherapy trials with regimens containing ofloxacin and rifampicin for multibacillary leprosy patients.
    Sampoonachot P; Bundit C; Kuhacharoen N; Peerapakorn S; Kampirapap K; Poomlek A; Bampenyu S; Tiasiri S; Rungruang S; Surasondhi S; Supanwanit S; Wiriyawipart S
    J Med Assoc Thai; 1996 Apr; 79(4):210-7. PubMed ID: 8708505
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Single dose multidrug therapy for single lesion paucibacillary leprosy.
    Porichha D
    Indian J Lepr; 1998; 70(2):213-4; author reply 219-21. PubMed ID: 9724858
    [No Abstract]   [Full Text] [Related]  

  • 43. Nasal mucosa and skin of smear-positive leprosy patients after 24 months of fixed duration MDT: histopathological and microbiological study.
    Ebenezer GJ; Job A; Abraham S; Arunthathi S; Rao PS; Job CK
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):292-7. PubMed ID: 10575409
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term evaluation of immune status in leprosy patients undergoing multiple drug therapy.
    Vu TT; Hoang TL; Nguyen DQ; Ho ML; Nguyen DH; Le TH; Dang DT; Nguyen QA; Le TP; Tran HK
    Int J Lepr Other Mycobact Dis; 1994 Sep; 62(3):365-73. PubMed ID: 7963908
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally.
    Lockwood DN; Cunha Mda G
    Lepr Rev; 2012 Sep; 83(3):241-4. PubMed ID: 23356024
    [No Abstract]   [Full Text] [Related]  

  • 47. Relapse of multibacillary leprosy after treatment with daily rifampin plus ofloxacin for four weeks.
    Ji B
    Int J Lepr Other Mycobact Dis; 1998 Sep; 66(3):391-2. PubMed ID: 9934368
    [No Abstract]   [Full Text] [Related]  

  • 48. In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice.
    Dhople AM; Ibanez MA
    Arzneimittelforschung; 1994 Apr; 44(4):563-5. PubMed ID: 8011013
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Generalized annular borderline tuberculoid leprosy and update in management of Hansen's disease.
    Young RJ; Gilson RT; Elston DM
    Cutis; 2000 Apr; 65(4):203-6. PubMed ID: 10795079
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The frequency of drug resistance mutations in Mycobacterium leprae isolates in untreated and relapsed leprosy patients from Myanmar, Indonesia and the Philippines.
    Matsuoka M; Budiawan T; Aye KS; Kyaw K; Tan EV; Cruz ED; Gelber R; Saunderson P; Balagon V; Pannikar V
    Lepr Rev; 2007 Dec; 78(4):343-52. PubMed ID: 18309708
    [TBL] [Abstract][Full Text] [Related]  

  • 51. DNA amplification for detection of leprosy and assessment of efficacy of leprosy chemotherapy.
    Kampirapap K; Singtham N; Klatser PR; Wiriyawipart S
    Int J Lepr Other Mycobact Dis; 1998 Mar; 66(1):16-21. PubMed ID: 9614835
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intrabacterial sodium-to-potassium ratios and ATP contents of Mycobacterium leprae from ofloxacin-treated patients.
    Dietz M; Haas M; Lindner B; Dhople AM; Tebebe YB; Seydel U
    Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):548-57. PubMed ID: 1802937
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rifampicin/minocycline and ofloxacin (ROM) for single lesions--what is the evidence?
    Lockwood DN
    Lepr Rev; 1997 Dec; 68(4):299-300. PubMed ID: 9503865
    [No Abstract]   [Full Text] [Related]  

  • 54. Chemotherapy trials in MB leprosy using conventional and newer drugs pefloxacin and minocycline.
    Katoch K; Katoch VM; Natrajan M; Sharma VD; Singh HB; Gupta UD
    Indian J Dermatol Venereol Leprol; 2000; 66(1):18-25. PubMed ID: 20877014
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relapse rates and a 10-year follow-up of a 6-week quadruple drug regimen for multibacillary leprosy.
    Pattyn S; Grillone S
    Lepr Rev; 2002 Sep; 73(3):245-7. PubMed ID: 12449889
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of NASBA RNA amplification for detection of Mycobacterium leprae in skin biopsies from untreated and treated leprosy patients.
    van der Vliet GM; Cho SN; Kampirapap K; van Leeuwen J; Schukkink RA; van Gemen B; Das PK; Faber WR; Walsh GP; Klatser PR
    Int J Lepr Other Mycobact Dis; 1996 Dec; 64(4):396-403. PubMed ID: 9030105
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Single dose multidrug therapy for single lesion paucibacillary leprosy.
    Kars HK
    Indian J Lepr; 1998; 70(2):214-5; author reply 219-21. PubMed ID: 9724859
    [No Abstract]   [Full Text] [Related]  

  • 58. Single-dose treatment for single lesion leprosy; histopathological observations.
    Shinde A; Khopkar U; Pai VV; Ganapati R
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):328-30. PubMed ID: 11221099
    [No Abstract]   [Full Text] [Related]  

  • 59. Screening of drugs for activity against Mycobacterium leprae.
    Baohong J; Matsuo Y; Colston MJ
    Int J Lepr Other Mycobact Dis; 1987 Dec; 55(4 Suppl):836-42. PubMed ID: 3325576
    [No Abstract]   [Full Text] [Related]  

  • 60. A study on trend of relapse in leprosy and factors influencing relapse.
    Ali MK; Thorat DM; Subramanian M; Parthasarathy G; Selvaraj U; Prabhakar V
    Indian J Lepr; 2005; 77(2):105-15. PubMed ID: 16044808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.